What ophthalmic drugs is Allvivo developing?

Allvivo is developing BRM424 for neurotrophic keratitis and BRM411 for glaucoma.

What is the status of BRM424's clinical trial?

Phase 2 enrollment in the US and Brazil is nearly complete, with an EOP2 meeting with the FDA planned for Q3 this year.

What is the progress of licensing negotiations?

Multiple international pharma companies are in due diligence for BRM424, with one in term negotiation. BRM411 has a regional proposal from an Asian company.

AI News NQ Analysis

Allvivo: Progress in Ophthalmic Drug Licensing, Aiming to Complete Negotiations by Year-End

NQ Score 0/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Allvivo Biomedical Chairman Lin Chun announced that the Phase 2 clinical trial enrollment for its novel drug BRM424 (for neurotrophic keratitis) is nearly complete. Multiple international pharmaceutical companies have entered due diligence, with licensing negotiations expected to be completed by the end of this year. Additionally, a regional licensing proposal has been received from an Asian pharmaceutical company for its glaucoma drug BRM411.

AI Analysis

Frequently Asked Questions

Q: What ophthalmic drugs is Allvivo developing?: A: Allvivo is developing BRM424 for neurotrophic keratitis and BRM411 for glaucoma.
Q: What is the status of BRM424's clinical trial?: A: Phase 2 enrollment in the US and Brazil is nearly complete, with an EOP2 meeting with the FDA planned for Q3 this year.
Q: What is the progress of licensing negotiations?: A: Multiple international pharma companies are in due diligence for BRM424, with one in term negotiation. BRM411 has a regional proposal from an Asian company.